MINE方案解救治疗复发或难治性非霍奇金淋巴瘤近期疗效观察

 目的　观察MINE方案解救治疗复发或难治的中度恶性非霍奇金淋巴瘤（NHL）的近期疗效和不良反应。方法　45例经CHOP或CHOP类方案治疗失败的NHL患者接受2～6个周期的MINE方案化疗。异环磷酰胺（IFO）1.5 g／m2静脉滴注，第1天至第3天，配合美斯钠（Mesna）400 mg／次分别于IFO后0、4、8 h静脉滴注，第1天至第3天；米托蒽醌（MIT）10 mg／m2静脉滴注，第1天；依托泊苷（VP16）65 mg／m2静脉滴注，第1天至第3天，以21～28 d为1个周期。疗效和不良反应按WHO标准判定。结果　完全缓解（CR）9例，部分缓解（PR）15例，稳定（SD）13例，进展（PD）8例，总有效率（RR）53.3 %。主要的不良反应为骨髓抑制、胃肠道反应和脱发。结论　MINE方案是复发或难治中度恶性NHL安全有效的解救治疗方案，值得进一步临床研究。

Clinical observation on short-term efficacy of MINE regimen for patients with recurrent and refractory NHL

Objective To investigate the efficacy and side effects of MINE regimen, as a salvage regimen, in treating patients with recurrent and refractory intermediate grade non-Hodgkin lymphoma(NHL).Methods 45 patients failing to CHOP or CHOP-like regimen were treated with MINE regimen and every patient had received 2-6 cycles of treatment. IFO 15 g/m2, ivgtt on d1-3, combined with mesna 400 mg iv for3 times on Oh, 4h, 8h after IFO ivgtt; MIT 10 mg/m2 ivgtt on dl; VP1665 mg/m2 ivgtt on d1-3. 21-28 daysconsisted of one cycle. The therapeutic effects and side effects were evaluated according to the WHO criteria.Results In all 45 patients, 53.3 % of overall response rate were achieved CR for 9 cases, 15 cases PR, 13 cases SD and 8 cases PD. Main side effects were myelosuppression, nausea, vomit, alopecia, etc. Conclusion MINE regimen is an effective and safe salvage regimen in treating patients with recurrent and refractory intermediate grade NHL. Further clinical study on the application of MINE regimen is recommended.